ANALYTICAL SERVICES CENTER FOR MEDICATIONS DEVELOPMENT

NIDA药物治疗和药物滥用的医疗后果司（DPMCDA）支持研究和开发治疗药物成瘾的新药物。这一发展的一个关键方面涉及对新药物的代谢、药代动力学和临床药理学的研究。这些研究的生物样本需要通过高度灵敏和特异性的方法定量测定研究药物及其代谢产物和滥用物质。该合同的目的是通过提供一个能够对各种化合物进行分析的中央分析设施，支持研究所在这些领域的努力，非法药物、潜在药物及其代谢物以及内源性物质，以支持药物开发。

The Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA) of NIDA supports research and development of new medications for the treatment of drug addictions. A critical aspect of this development involves studies on the metabolism, pharmacokinetics and clinical pharmacology of new medications. Biological specimens from these studies require quantitative determination of the study medication and its metabolites and the abused substances by highly sensitive and specific methodology. The purpose of this contract is to support the Institute's efforts in these areas by providing a centralized analytical facility capable of carrying out analyses on a wide variety of compounds, e.g., illicit drugs, potential medications and their metabolites, as well as endogenous substances, in biological fluids in support of medications development.